A national strategy for a technology problem is a statement of intent, not a performance record. Water Finance and Management reported that the U.S. Environmental Protection Agency launched the first agency-wide PFAS Technology, Evaluation, Coordination, and Harmonization (PFAS TECH) strategy, and that the agency said the effort will help "springboard technology innovation on PFAS". The summary of that launch, published in Water Finance and Management, describes an organizing framework for federal activity. It does not describe a treatment process shown to work at any particular plant. For a utility technology review, that gap is the working question.
What a strategy can and cannot settle
Program strategies typically coordinate research, set priorities, and point attention toward gaps. Those are useful functions, and a utility benefits when studies become more common and more comparable. They do not validate a specific sorbent, ion exchange resin, membrane, or destruction method for your raw water. Performance depends on the water being treated. Competing ions, natural organic matter, pH, temperature, and the mix of PFAS compounds all shift how media and membranes behave, and a result obtained in one matrix often does not transfer cleanly to another. A strategy can make more studies exist. It cannot make the local match for you.
Reading a vendor's evidence against your matrix
When a technology review begins, the first records to request are the test conditions. Ask what water was used, whether it was synthetic or source water, which compounds were spiked or measured, what flow and contact time were applied, and how long the run lasted before breakthrough or the next sampling event. A bench test on clean water and a pilot run on your intake answer different questions. Both can have value, but they belong in separate sections of the file so no one later reads a clean-water number as a field result.
Scale is the second gap. Bench results reflect contact time and flow in a small column. Pilot units reveal fouling, backwash behavior, and the handling burden that bench data cannot show. Full-scale operation adds maintenance cycles, spent media or concentrate handling, and the staffing needed to run the system continuously. Each step lowers uncertainty and raises cost. A review should state which step the evidence actually reached, not the step implied by a brochure or a conference slide.
Process type also changes the record you must keep. Sorbent systems generate spent media with disposal terms that need to be set before purchase. Membrane systems produce a concentrate stream and require pretreatment and monitoring of recovery and integrity. Destruction technologies raise their own questions about byproducts and verification. A federal strategy that names several research paths does not resolve which of these tradeoffs fits your operation. The tradeoff is local, and so is the answer.
What to record before a decision
A defensible technology file has four parts. The first is source water characterization across the seasons you will actually operate, not a single sampling date. The second is the analytical method and its reporting limit, since a non-detect means different things under different limits. The third is the pilot or demonstration design, with start and stop dates, flow rates, and the operating envelope. The fourth is the change-out or regeneration trigger the vendor proposes, along with the basis for it. Missing any one of these means a reported performance figure cannot be compared against another system or against your own targets.
Keep those records with the technology review rather than in the vendor's folder. Vendor files tend to travel with the vendor, and a utility that changes suppliers, or changes staff, may find that the only copy of the test basis has left the building. A plain internal index that lists each study, its matrix, its scale, and its date will outlast most procurement cycles.
Federal programs can also widen the pool of studies a utility may read. That is useful, but a larger literature raises the risk of citing a favorable result without checking its conditions. Tag each study by matrix, scale, compound set, and test date before it enters a board memo or a capital justification. An older study from a different water is still evidence, but it is evidence about that water, and the memo should say so.
The practical rule is straightforward. Treat a national strategy as a signal about where research is heading and where funding may follow. Make the adoption decision on your own water, your own pilot data, and a record that lets a later reviewer see exactly what was tested and under which conditions. The strategy will not write that record for you, and the uncertainty that remains after a careful review should be stated in the file rather than smoothed over in the summary.